{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:48Z","timestamp":1793183208733,"version":"4.5.0"},"reference-count":71,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe the pharmacology, efficacy, safety, and potential role of vonoprazan with amoxicillin or amoxicillin and clarithromycin for the treatment of Helicobacter pylori infection in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched using the terms: (vonoprazan OR voquezna) AND (\u201c H. pylori\u201d OR \u201c Helicobacter pylori\u201d) AND amoxicillin with no date limitations up to November 3, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Studies assessing the efficacy and safety of vonoprazan with amoxicillin and\/or clarithromycin were included and divided into 3 groups based on different comparisons between treatment regimens used in each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Ten clinical trials and 17 observational studies were included. Vonoprazan-based therapy demonstrated greater acid inhibition and similar or higher efficacy than proton-pump inhibitor (PPI)-based therapy in treatment-na\u00efve patients and with clarithromycin-resistant infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Proton-pump inhibitor-based therapies have not reached the desired successful eradication rate of 90% for H. pylori infection. Vonoprazan-based therapies being at least as effective as PPI-based therapies offer an alternative for patients with H. pylori infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Vonoprazan-based therapies were effective and well tolerated for the treatment of H. pylori infection in adults. These regimens provide an important alternative with prolonged acid inhibition, lower potential for CYP2C19 polymorphism, and at least comparable efficacy and safety versus PPI-based therapies in patients with H. pylori infections. Thus, vonoprazan-based therapy should be considered for certain patients, for example, those with failure to PPI-based treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221149708","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:52:18Z","timestamp":1674449538000},"page":"1185-1197","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of\n                    <i>Helicobacter pylori<\/i>\n                    Infection"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-3000","authenticated-orcid":false,"given":"Ligang","family":"Liu","sequence":"first","affiliation":[{"name":"Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[{"name":"Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA"},{"name":"College of Medicine, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"bibr1-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.007"},{"key":"bibr2-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i29.3204"},{"key":"bibr3-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"bibr4-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13414"},{"key":"bibr5-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-018-0206-y"},{"key":"bibr6-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.059"},{"key":"bibr7-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2013.811206"},{"key":"bibr8-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00449-x"},{"key":"bibr9-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i16.1907"},{"key":"bibr10-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1097\/qco.0000000000000396"},{"key":"bibr11-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776"},{"key":"bibr12-10600280221149708","unstructured":"VOQUEZNA (Vonoprazan triple Pak and dual Pak) [package insert]. Buffalo Grove IPP, Inc; 2022. Accessed July 22, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215152s000,215153s000lbl.pdf"},{"key":"bibr13-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-010-0137-9"},{"key":"bibr14-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7"},{"key":"bibr15-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274"},{"key":"bibr16-10600280221149708","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001735"},{"key":"bibr17-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"bibr18-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i34.5097"},{"key":"bibr19-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2007.00508.x"},{"key":"bibr20-10600280221149708","unstructured":"Lexi-Drugs online. Voquezna Triple Pak. Lexi-Comp Iuaholcl. https:\/\/online-lexi-com.proxy.lib.ohio-state.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7221647?cesid=85vXIcin9pi&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dvoquezna%2Btriple%2Bpak%26t%3Dname%26acs%3Dtrue%26acq%3DVoquezna%2BTriple%2BPak"},{"key":"bibr21-10600280221149708","unstructured":"Food and Drug Administration. Drug approval package: VOQUEZNA integrated review. Date unknown. Accessed September 22, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215152Orig1s000,215153Orig1s000IntegratedR.pdf"},{"key":"bibr22-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"bibr23-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1009"},{"key":"bibr24-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15700"},{"key":"bibr25-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"bibr26-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4385161"},{"key":"bibr27-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12456"},{"key":"bibr28-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319954"},{"key":"bibr29-10600280221149708","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.38.4.5436"},{"key":"bibr30-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"bibr31-10600280221149708","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7833"},{"key":"bibr32-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17070"},{"key":"bibr33-10600280221149708","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-4133"},{"key":"bibr34-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01709-4"},{"key":"bibr35-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1159\/000502287"},{"key":"bibr36-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1159\/000501608"},{"key":"bibr37-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-018-0281-x"},{"key":"bibr38-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12398"},{"key":"bibr39-10600280221149708","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.253.7hp"},{"key":"bibr40-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.182"},{"key":"bibr41-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2016.04.009"},{"key":"bibr42-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010116"},{"key":"bibr43-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3892\/br.2018.1111"},{"key":"bibr44-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i4.668"},{"key":"bibr45-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1159\/000454762"},{"key":"bibr46-10600280221149708","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v7.i4.550"},{"key":"bibr47-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4305-0"},{"key":"bibr48-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.16-86"},{"key":"bibr49-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13349"},{"key":"bibr50-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1159\/000490889"},{"key":"bibr51-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00738.x"},{"key":"bibr52-10600280221149708","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001828"},{"key":"bibr53-10600280221149708","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001031"},{"key":"bibr54-10600280221149708","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2521-18"},{"key":"bibr55-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12495"},{"key":"bibr56-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.012"},{"key":"bibr57-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1159\/000504939"},{"key":"bibr58-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13637"},{"key":"bibr59-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2324-1"},{"key":"bibr60-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00053"},{"key":"bibr61-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173964"},{"key":"bibr62-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.863"},{"key":"bibr63-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(22)61292-7"},{"key":"bibr64-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000543"},{"key":"bibr65-10600280221149708","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100645"},{"key":"bibr66-10600280221149708","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0127"},{"key":"bibr67-10600280221149708","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.192757"},{"key":"bibr68-10600280221149708","unstructured":"ClinicalTrials.gov. Efficacy and safety of vonoprazan as first-line treatment for Helicobacter pylori eradication. Date unknown. Accessed November 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04907747\/"},{"key":"bibr69-10600280221149708","unstructured":"ClinicalTrials.gov. The evaluation of triple therapy with vonoprazan, amoxicillin and bismuth for eradication of Helicobacter pylori. Date unknown. Accessed November 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05189444"},{"key":"bibr70-10600280221149708","unstructured":"ClinicalTrials.gov. A RCT of triple therapy with proton pump inhibitor vs vonoprazan for Helicobacter pylori gastritis (TRIVON). Date unknown. Accessed November 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03908619"},{"key":"bibr71-10600280221149708","unstructured":"ClinicalTrials.gov. Vonoprazan Hp dual or triple eradication regimens. Date unknown. Accessed November 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05345210"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221149708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221149708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221149708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:01Z","timestamp":1777374781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221149708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10600280221149708"],"URL":"https:\/\/doi.org\/10.1177\/10600280221149708","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}